These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15718695)

  • 41. Professional development of statisticians in the pharmaceutical sector: evolution over the past decade and into the future.
    Lewis T
    Pharm Stat; 2008; 7(3):158-69. PubMed ID: 18720452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Applying computational modeling to drug discovery and development.
    Kumar N; Hendriks BS; Janes KA; de Graaf D; Lauffenburger DA
    Drug Discov Today; 2006 Sep; 11(17-18):806-11. PubMed ID: 16935748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Partnership between small biotech and big pharma.
    Wiederrecht GJ; Hill RG; Beer MS
    IDrugs; 2006 Aug; 9(8):560-4. PubMed ID: 16871465
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biomarkers for TB treatment response: challenges and future strategies.
    Walzl G; Ronacher K; Djoba Siawaya JF; Dockrell HM
    J Infect; 2008 Aug; 57(2):103-9. PubMed ID: 18649943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Organizing for innovation: towards successful translational research.
    West W; Nightingale P
    Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A decade of fragment-based drug design: strategic advances and lessons learned.
    Hajduk PJ; Greer J
    Nat Rev Drug Discov; 2007 Mar; 6(3):211-9. PubMed ID: 17290284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effective executive management in the pharmaceutical industry.
    Tran H; Kleiner BH
    J Health Care Finance; 2005; 32(1):8-15. PubMed ID: 18972973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. What's next in translational medicine?
    Littman BH; Di Mario L; Plebani M; Marincola FM
    Clin Sci (Lond); 2007 Feb; 112(4):217-27. PubMed ID: 17223795
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development, implementation and pilot evaluation of a Web-based Virtual Patient Case Simulation environment--Web-SP.
    Zary N; Johnson G; Boberg J; Fors UG
    BMC Med Educ; 2006 Feb; 6():10. PubMed ID: 16504041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The difficulties industry is facing with investigators.
    Blackledge GR
    Eur J Cancer; 2005 Oct; 41(15):2210-2. PubMed ID: 16214043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. If we designed airplanes like we design drugs...
    Woltosz WS
    J Comput Aided Mol Des; 2012 Jan; 26(1):159-63. PubMed ID: 22139474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A priori performance predictions in the pharmaceutical sciences.
    Hancock BC; Morris KR; Wildfong PL
    Int J Pharm; 2011 Oct; 418(2):149-50. PubMed ID: 21726614
    [No Abstract]   [Full Text] [Related]  

  • 56. Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development.
    Krishna R; Schaefer HG; Bjerrum OJ
    Eur J Pharm Sci; 2007 May; 31(1):62-7. PubMed ID: 17408933
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiscale mechanistic modeling in pharmaceutical research and development.
    Kuepfer L; Lippert J; Eissing T
    Adv Exp Med Biol; 2012; 736():543-61. PubMed ID: 22161351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trial watch: Phase II failures: 2008-2010.
    Arrowsmith J
    Nat Rev Drug Discov; 2011 May; 10(5):328-9. PubMed ID: 21532551
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmaceutical trials in the research program.
    Steven ID
    Aust Fam Physician; 1996 Sep; 25(9 Suppl 2):S51-2. PubMed ID: 8854406
    [No Abstract]   [Full Text] [Related]  

  • 60. Simulation of clinical trials.
    Holford NH; Kimko HC; Monteleone JP; Peck CC
    Annu Rev Pharmacol Toxicol; 2000; 40():209-34. PubMed ID: 10836134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.